Discovery of Potent and Selective THRβ Agonists Based on an N-Benzoylglycine Scaffold for the Treatment of Metabolic Disorders.
An N-benzoylglycine scaffold is designed as a new chemotype, which provides selectivity for the THRβ receptor against THRα while preserving key interactions with the arginine-rich positively charged pocket and establishes the N-benzoylglycine scaffold as a promising chemotype for developing selective, orally active THR...